{
    "other_tests": [
        {
            "procedure_name": "Bone Turnover Markers Assessment",
            "date": "Not specified",
            "findings": "Alkaline phosphatase levels dropped within the normal range and remained at normal levels for 5 months after the final dose of denosumab.",
            "changes_over_time": "After denosumab treatment, bone turnover markers TSAP, BAP, TRAP5b, and NTX levels started to increase again after 6 weeks."
        },
        {
            "procedure_name": "Calcium Level Monitoring",
            "date": "Not specified",
            "findings": "Severe hypocalcemia developed after the first injection of denosumab, with ionized calcium levels dropping to 0.71 mmol/L.",
            "changes_over_time": "No hypocalcemia was observed after the second dose of denosumab."
        },
        {
            "procedure_name": "ECG Monitoring",
            "date": "Not specified",
            "findings": "Regular ECG readings showed no abnormalities during treatment.",
            "changes_over_time": "Not specified."
        },
        {
            "procedure_name": "Genetic Analysis",
            "date": "Not specified",
            "findings": "Homozygous mutation in the osteoprotegerin gene TNFRSF11B was identified.",
            "changes_over_time": "Not specified."
        },
        {
            "procedure_name": "Serum PTH Monitoring",
            "date": "Not specified",
            "findings": "Elevated PTH levels were noted after the first injection of denosumab.",
            "changes_over_time": "Not specified."
        }
    ]
}